Crinetics Pharmaceuticals Inc.
Rating
Updated: Aug 31, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent en...
Latest News
3 days ago · defenseworld.net
Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends. Analyst Ratings This is a summary of current
1 month ago · businesswire.com
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNXNEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this considerati.
2 months ago · globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—CRNX, PSBQ, D, and NEENEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
2 months ago · zacks.com
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue EstimatesCrinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago.
2 months ago · globenewswire.com
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAnnounced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
2 months ago · prnewswire.com
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2 months ago · globenewswire.com
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public ShareholdersMILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.
3 months ago · fool.com
Why This Pharmaceutical Stock Jumped Close to 100% This WeekIt is getting acquired by a larger firm in the sector.
3 months ago · 247wallst.com
Why Crinetics Stock Soared 99% This WeekCrinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
3 months ago · prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) related to its sale to Vertex Pharmaceuticals Incorporated.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CRNX